
    
      This is a multi-center open-label, long-term study in LBD subjects with RBD and/or VHs.
      Eligible subjects who completed a previous nelotanserin VH or RBD study and choose to
      participate in this open-label study will receive 20, 40, 60, or 80 mg nelotanserin once
      daily for 24 weeks.
    
  